Search Site:

Global Activities

General

Manufacture & Supply

Laboratory Facilities

General

Global Activities

27/01/2009

Dexcel Pharma conducts its operations in 19 countries through local subsidiaries and distributors:

In the US, Dexcel Pharma Technologies, Ltd. was first to file, obtain approval for, and launch generic Omeprazole OTC 20mg to the 26 largest chain drugstores, in cooperation with Perrigo (Prilosec^® $800m market).

In the UK, Dexcel-Pharma Limited has a 40%+ market share with its 6 largest products, and an excellent long-term relationship (including 'own label' supply) with the leading chain pharmacy stores.

In Germany, Dexcel Pharma GmbH is one of the fastest growing generic companies. It will continue to enjoy significant growth and an expanding product range, through aggressive bidding in all future sick fund tenders (established by a revolutionary 2007 law forcing pharmacies to dispense the cost-effective generics of the winning tenders).

Dexcel Pharma's strategy is"first-to-file" in the US and "day one" in the EU.

Dexcel Pharma has obtained approval for and launched Omepazole Rx 20mg in Australia, the first of many products to be launched there.

Dexcel Pharma's innovative dental product PerioChip^® is marketed in the US (NDA), 12 EU member states and Singapore, and is soon to be launched in Korea.

Search Site:

General

Global Activities 27/01/2009

Global Activities

27/01/2009